The FDA publishes warning letters on its website. Every warning letter sent to a dietary supplement brand is publicly available, indexed by year and company. Reading them is free. Ignoring them is expensive. The violation patterns that appear in FDA warning letters for supplements are consistent enough to function as a compliance checklist for any brand in the category.
Disease Claims: The Most Consistent Violation
The single most common violation in FDA warning letters for dietary supplement brands is making disease claims — using language on labels, websites, or marketing materials that explicitly states or implies the product treats, cures, mitigates, or prevents a named disease.
FDA evaluates disease claims under 21 CFR 101.93(g)'s ten-factor test. Warning letters consistently cite:
Explicit disease names on labels or in marketing copy ("for diabetes," "treats arthritis," "for people with Alzheimer's")
Implied disease claims through symptom language ("lowers blood pressure," "reduces joint inflammation," "relieves anxiety")
Drug comparisons ("works like metformin," "natural statin alternative")
Marketing context that converts otherwise permissible structure/function claims into disease claims (disease awareness imagery, testimonials from diagnosed patients, targeting posts at disease-specific communities)
Warning letters frequently quote directly from brand websites, Amazon listings, and social media posts — not just physical labels. FDA's disease claim review covers every channel where the product is marketed.
Missing or Incorrect FDA Disclaimer
Structure/function claims on supplement labels require the FDA disclaimer under 21 CFR 101.93(b)-(d):
"This statement has not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease."
Warning letters cite disclaimer violations for:
Missing disclaimer entirely when structure/function claims are present
Incorrect disclaimer text (modified wording, truncated language)
Disclaimer placed too far from the claim it qualifies
Disclaimer in type too small to meet 21 CFR 101.93(d)'s legibility requirements
Disclaimer absent on the website or marketing materials that contain the structure/function claim
Unauthorized Health Claims
Health claims — claims that a product or nutrient affects a disease or health-related condition — require FDA authorization under 21 CFR 101.14. Only claims that have gone through the authorized health claim process (or qualified health claim petition process) may be used.
Warning letters cite brands that use health claim language — "reduces the risk of heart disease," "helps prevent osteoporosis," "reduces the risk of cancer" — without authorization, or that adapt authorized claim language in ways that exceed the authorized scope.
cGMP Violations
Current Good Manufacturing Practice violations under 21 CFR Part 111 appear frequently in warning letters that follow facility inspections (FDA Form 483 observations). Common cGMP violations include:
Failure to establish and follow written procedures for manufacturing operations
Inadequate identity testing of incoming ingredients
Failure to conduct finished product testing for identity, purity, and strength
Inadequate recordkeeping for batch production
Failure to investigate consumer complaints
cGMP warning letters often accompany product quality issues — undeclared ingredients, label quantity overages, contamination — and can result in mandatory recalls.
New Dietary Ingredient Violations
Brands marketing products containing New Dietary Ingredients without the required 75-day pre-market notification to FDA (21 U.S.C. 350b) appear in warning letters. NDI violations are often discovered in conjunction with disease claim reviews — FDA examines the full label and finds both issues simultaneously.
Website and Social Media as the Warning Letter Trigger
A review of recent FDA warning letters shows a consistent pattern: the triggering violation is frequently on a brand's website or social media, not on the physical product label. FDA's enforcement posture has moved firmly into digital channels. Warning letters quote:
Website product pages with disease claims absent from the label
Blog posts on the brand's website that make therapeutic claims for the product
Social media posts and influencer content attributed to the brand
Amazon listing copy with disease language
A brand with a compliant label and a non-compliant website faces the same warning letter exposure as a brand with a non-compliant label.
What Happens After a Warning Letter
Warning letters require a response within 15 business days. The response must address each cited violation and describe corrective actions. Failure to respond adequately can escalate to:
Injunction (court order requiring cessation of the violative conduct)
Seizure of products
Consent decree (court-supervised compliance agreement)
Criminal prosecution in extreme cases
Warning letters also trigger secondary consequences: retailer reviews (some retailers require warning letter disclosure in supplier agreements), marketplace enforcement (Amazon has removed listings following FDA warning letters), and investor/partner scrutiny.
Warning letters are predictable — the violation patterns are consistent enough to be a compliance checklist
Truli's scanning is built on the same violation categories FDA consistently cites in warning letters — disease claims across labels, websites, ads, and social content; missing disclaimers; unauthorized health claims; and NDI status flags. Identifying these issues internally, before FDA does, is exactly what compliance scanning is for.
A note from Truli: Truli is not a law firm, and this article does not constitute or contain legal advice or create an attorney-client relationship. When determining your obligations and compliance with respect to relevant laws and regulations, you should consult a licensed attorney.
